Innate Pharma reported a cash position of €56.4 million as of September 30, 2025, providing runway through the end of Q3 2026. The presentation focused primarily on clinical milestones rather than ...
Innate Pharma reported revenue of €4.9 million for H1 2025, with operating expenses of €30.3 million. The company maintained a cash position of €70.4 million as of June 30, 2025, which management ...
Innate Pharma outlined several upcoming catalysts for 2025-2027. For proprietary assets, these include safety and preliminary efficacy data from the IPH6501 Phase 1 trial in 2025, the ongoing transfer ...
Innate Pharma (EURONEXT:IPH.PA, NASDAQ: IPHA) presented its Q3 2025 business update and financial results on November 13, 2025, emphasizing progress across its clinical pipeline. The company’s stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback